Exelixis Inc (EXEL):企業の財務・戦略的SWOT分析

◆英語タイトル:Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C8766
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,125見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Exelixis Inc (EXEL) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma; and Cotellic (cobimetinib) is developed in combination with vemurafenib for the treatment of patients with mutation-positive advanced melanoma. The company also enters into collaborative partnerships with pharmaceutical and biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in South San Francisco, California, the US.

Exelixis Inc Key Recent Developments

Oct 08,2018 Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
Sep 21,2018 TOPC : Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma[Newswire : Healthcare-BW]
Sep 19,2018 TOPC : Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma[Newswire : Healthcare-BW]
Aug 01,2018 Exelixis announces second quarter 2018 financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Exelixis Inc – Key Facts 6
Exelixis Inc – Key Employees 7
Exelixis Inc – Key Employee Biographies 8
Exelixis Inc – Major Products and Services 9
Exelixis Inc – History 10
Exelixis Inc – Company Statement 13
Exelixis Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Company Overview 16
Exelixis Inc – Business Description 17
Exelixis Inc – Corporate Strategy 18
Exelixis Inc – SWOT Analysis 19
SWOT Analysis – Overview 19
Exelixis Inc – Strengths 19
Exelixis Inc – Weaknesses 20
Exelixis Inc – Opportunities 21
Exelixis Inc – Threats 22
Exelixis Inc – Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios – Capital Market Ratios 24
Financial Ratios – Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios – Interim Ratios 28
Financial Ratios – Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
Exelixis Inc, Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
Oct 08, 2018: Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress 33
Oct 08, 2018: Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress 39
Sep 21, 2018: TOPC : Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma[Newswire : Healthcare-BW] 46
Sep 19, 2018: TOPC : Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma[Newswire : Healthcare-BW] 48
Sep 19, 2018: TOPC : Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma[Newswire : Healthcare-BW] 49
Sep 19, 2018: TOPC : Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma[Newswire : Healthcare-BW] 50
Aug 01, 2018: Exelixis announces second quarter 2018 financial results and provides corporate update 51
May 22, 2018: Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy 54
Apr 09, 2018: Exelixis Elects Dr. Maria Freire to Its Board of Directors 55
Nov 01, 2017: Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update 56
Section 6 – Appendix 59
Methodology 59
Ratio Definitions 59
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
Exelixis Inc, Key Facts 6
Exelixis Inc, Key Employees 7
Exelixis Inc, Key Employee Biographies 8
Exelixis Inc, Major Products and Services 9
Exelixis Inc, History 10
Exelixis Inc, Subsidiaries 15
Exelixis Inc, Key Competitors 23
Exelixis Inc, Ratios based on current share price 24
Exelixis Inc, Annual Ratios 25
Exelixis Inc, Annual Ratios (Cont...1) 26
Exelixis Inc, Interim Ratios 28
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
Exelixis Inc, Recent Deals Summary 32
Currency Codes 59
Capital Market Ratios 59
Equity Ratios 60
Profitability Ratios 60
Cost Ratios 61
Liquidity Ratios 61
Leverage Ratios 62
Efficiency Ratios 62

List of Figures
Exelixis Inc, Performance Chart (2013 - 2017) 27
Exelixis Inc, Ratio Charts 29
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31

★海外企業調査レポート[Exelixis Inc (EXEL):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SWECO AB:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' SWECO AB Mergers and Acquisitio …
  • Mega Uranium, Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Mega Uranium, Ltd. Mergers and …
  • Novo Nordisk AS (NOVO B)-医療機器分野:企業M&A・提携分析
    Summary Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company’s product …
  • Black Stone Minerals, L.P. (BSM):企業のM&A・提携動向(石油・ガス分野)
    Summary Black Stone Minerals, L.P. (Black Stone) is an oil and gas company that explores and produces a range of mineral deposits. The company's activities comprise leasing minerals to exploration and production companies; participating on a working interest basis when economics are favorable; and a …
  • Siemens Building Technologies:企業の戦略的SWOT分析
    Siemens Building Technologies - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • The Scoular Company:企業概要およびSWOT分析
    Summary Canadean's "The Scoular Company: Consumer Packaged Goods - Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, com …
  • Dalton Pharma Services(製薬・医療分野):企業M&A動向
    Summary Dalton Pharma Services (Dalton) is a pharmaceutical company. The company provides pharmaceutical contract manufacturing services. Its products include building blocks, coelenterazines, drugs and metabolites, glitazones, gmp apis, excipients and reagents, heterocycles, labelled compounds, met …
  • Fukuoka REIT Corporation:企業概要・SWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Fukuoka REIT Corporation" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly …
  • International Rectifier Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' International Rectifier Corpora …
  • Vietnam Steel Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Vietnam Steel Corporation Merge …
  • Easyknit Properties Holdings Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Easyknit Properties Holdings Li …
  • North China Pharmaceutical Co Ltd (600812):製薬・医療:M&Aディール及び事業提携情報
    Summary North China Pharmaceutical Co Ltd (NCPC), a subsidiary of North China Pharmaceutical Group Corp is a pharmaceutical company that develops, produces and sells novel drugs and pharmaceutical related products. The company offers preparation products, nutrition, pharmaceutical raw materials and …
  • Jerusalem Insurance Company PLC:企業の戦略・SWOT・財務情報
    Jerusalem Insurance Company PLC - Strategy, SWOT and Corporate Finance Report Summary Jerusalem Insurance Company PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • National Express Group PLC:企業概要・SWOT・財務分析
    Summary Canadean's "National Express Group PLC : Travel and Tourism - Company Profile, SWOT and Financial Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business de …
  • 3D Systems Corporation:企業の戦略・SWOT・財務情報
    3D Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary 3D Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Exactech Inc:医療機器:M&Aディール及び事業提携情報
    Summary Exactech Inc (Exactech) is a medical device company that offers orthopedic implant devices and related surgical instruments. The company’s products comprise hip implants, shoulder implants, knee implants, extremity implants, biologics and spine, and other products. It also provides biologic …
  • The Blackstone Group L.P.:企業の戦略・SWOT・財務分析
    The Blackstone Group L.P. - Strategy, SWOT and Corporate Finance Report Summary The Blackstone Group L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sherritt International Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Sherritt International Corporat …
  • The Hain Celestial Group Inc (HAIN):企業の財務・戦略的SWOT分析
    The Hain Celestial Group Inc (HAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Atos SE:企業の戦略・SWOT・財務分析
    SummaryAtos SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - Deta …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆